ACADIA Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $18.405
- Today's High:
- $19.1
- Open Price:
- $19.1
- 52W Low:
- $12.24
- 52W High:
- $28.06
- Prev. Close:
- $18.98
- Volume:
- 1495375
Company Statistics
- Market Cap.:
- $3.35 billion
- Book Value:
- 2.471
- Revenue TTM:
- $517.24 million
- Operating Margin TTM:
- -43.23%
- Gross Profit TTM:
- $145.49 million
- Profit Margin:
- -41.76%
- Return on Assets TTM:
- -21.7%
- Return on Equity TTM:
- -45.89%
Company Profile
ACADIA Pharmaceuticals Inc had its IPO on 2004-05-27 under the ticker symbol ACAD.
The company operates in the Healthcare sector and Biotechnology industry. ACADIA Pharmaceuticals Inc has a staff strength of 511 employees.
Stock update
Shares of ACADIA Pharmaceuticals Inc opened at $19.1 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $18.41 - $19.1, and closed at $18.7.
This is a -1.48% slip from the previous day's closing price.
A total volume of 1,495,375 shares were traded at the close of the day’s session.
In the last one week, shares of ACADIA Pharmaceuticals Inc have increased by +1.08%.
ACADIA Pharmaceuticals Inc's Key Ratios
ACADIA Pharmaceuticals Inc has a market cap of $3.35 billion, indicating a price to book ratio of 6.0027 and a price to sales ratio of 4.7708.
In the last 12-months ACADIA Pharmaceuticals Inc’s revenue was $517.24 million with a gross profit of $145.49 million and an EBITDA of $-221570000. The EBITDA ratio measures ACADIA Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ACADIA Pharmaceuticals Inc’s operating margin was -43.23% while its return on assets stood at -21.7% with a return of equity of -45.89%.
In Q4, ACADIA Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 4.4%.
ACADIA Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -0.42
Its diluted EPS in the last 12-months stands at $-1.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.42. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ACADIA Pharmaceuticals Inc’s profitability.
ACADIA Pharmaceuticals Inc stock is trading at a EV to sales ratio of 4.2653 and a EV to EBITDA ratio of -9.9115. Its price to sales ratio in the trailing 12-months stood at 4.7708.
ACADIA Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $587.81 million
- Total Liabilities
- $125.63 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
ACADIA Pharmaceuticals Inc ended 2023 with $587.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $587.81 million while shareholder equity stood at $400.41 million.
ACADIA Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $125.63 million in other current liabilities, in common stock, $-2369551000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $114.85 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
ACADIA Pharmaceuticals Inc’s total current assets stands at $507.94 million while long-term investments were $0 and short-term investments were $301.98 million. Its net receivables were $62.20 million compared to accounts payable of $12.75 million and inventory worth $6.64 million.
In 2023, ACADIA Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, ACADIA Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $18.7
- 52-Week High
- $28.06
- 52-Week Low
- $12.24
- Analyst Target Price
- $18.84
ACADIA Pharmaceuticals Inc stock is currently trading at $18.7 per share. It touched a 52-week high of $28.06 and a 52-week low of $28.06. Analysts tracking the stock have a 12-month average target price of $18.84.
Its 50-day moving average was $19.4 and 200-day moving average was $16.85 The short ratio stood at 6.61 indicating a short percent outstanding of 0%.
Around 20.4% of the company’s stock are held by insiders while 9770.1% are held by institutions.
Frequently Asked Questions About ACADIA Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer’s disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.